Yvette Andersson1,2, L Bergkvist3,4, J Frisell5,6, J de Boniface6,7. 1. Department of Surgery, Västmanland County Hospital, 72189, Västerås, Sweden. yvette.andersson@regionvastmanland.se. 2. Center for Clinical Research, Västmanland County Hospital, Uppsala University, Västerås, Sweden. yvette.andersson@regionvastmanland.se. 3. Department of Surgery, Västmanland County Hospital, 72189, Västerås, Sweden. 4. Center for Clinical Research, Västmanland County Hospital, Uppsala University, Västerås, Sweden. 5. Department of Breast and Endocrine Surgery, Karolinska University Hospital, Stockholm, Sweden. 6. Department of Molecular Medicine and Surgery, Karolinska Institutet, Stockholm, Sweden. 7. Department of Surgery, Capio St Göran's Hospital, Stockholm, Sweden.
Abstract
PURPOSE: The clinical significance of lymph node micrometastases and isolated tumor cells (ITCs) in breast cancer is still controversial. After a median follow-up of 52 months, a report from the Swedish Multicenter Cohort Study presented a worse cancer-specific and event-free survival for patients with micrometastases than node-negative individuals, but could not demonstrate a significant difference in overall survival (OS). Due to the tendency of breast cancer to relapse after more than 5-10 years, we now report the long-term survival of the cohort. METHODS: Between September 2000 and January 2004, 3355 breast cancer patients were included in a prospective cohort. Sentinel lymph node biopsy was always performed. Patients were classified in four groups according to their overall nodal stage: node negative (N0, 2372), ITCs (113), micrometastases (123), and macrometastases (747). Kaplan-Meier survival estimates and Cox proportional hazard regression models were applied. RESULTS: Median follow-up was 156 months. Ten-year cancer-specific survival and OS were significantly lower in case of micrometastases than in N0 (84.7 vs. 93.5%, p = 0.001, and 75.5 vs. 84.2%, p = 0.046, respectively). In case of macrometastases, corresponding survival rates were 82.8 and 74.3%. Only for those aged less than 50 years, cancer-specific survival and OS were significantly worse in case of ITCs than N0. Patients with micrometastases received less often chemotherapy than those with macrometastases (24.4 vs. 53.9%). CONCLUSIONS: Lymph node micrometastases in breast cancer have a prognostic significance. This study demonstrates a similar survival for patients with micrometastases and those with macrometastases, possibly due to systemic undertreatment.
PURPOSE: The clinical significance of lymph node micrometastases and isolated tumor cells (ITCs) in breast cancer is still controversial. After a median follow-up of 52 months, a report from the Swedish Multicenter Cohort Study presented a worse cancer-specific and event-free survival for patients with micrometastases than node-negative individuals, but could not demonstrate a significant difference in overall survival (OS). Due to the tendency of breast cancer to relapse after more than 5-10 years, we now report the long-term survival of the cohort. METHODS: Between September 2000 and January 2004, 3355 breast cancerpatients were included in a prospective cohort. Sentinel lymph node biopsy was always performed. Patients were classified in four groups according to their overall nodal stage: node negative (N0, 2372), ITCs (113), micrometastases (123), and macrometastases (747). Kaplan-Meier survival estimates and Cox proportional hazard regression models were applied. RESULTS: Median follow-up was 156 months. Ten-year cancer-specific survival and OS were significantly lower in case of micrometastases than in N0 (84.7 vs. 93.5%, p = 0.001, and 75.5 vs. 84.2%, p = 0.046, respectively). In case of macrometastases, corresponding survival rates were 82.8 and 74.3%. Only for those aged less than 50 years, cancer-specific survival and OS were significantly worse in case of ITCs than N0. Patients with micrometastases received less often chemotherapy than those with macrometastases (24.4 vs. 53.9%). CONCLUSIONS: Lymph node micrometastases in breast cancer have a prognostic significance. This study demonstrates a similar survival for patients with micrometastases and those with macrometastases, possibly due to systemic undertreatment.
Authors: Lisa Rydén; Ida Skarping; Kristoffer Nilsson; Looket Dihge; Adam Fridhammar; Mattias Ohlsson; Linnea Huss; Pär-Ola Bendahl; Katarina Steen Carlsson Journal: Breast Cancer Res Treat Date: 2022-07-05 Impact factor: 4.624
Authors: Oscar Holmström; Nina Linder; Hannu Moilanen; Antti Suutala; Stig Nordling; Anders Ståhls; Mikael Lundin; Vinod Diwan; Johan Lundin Journal: PLoS One Date: 2019-03-19 Impact factor: 3.240
Authors: Mausam Patel; Chenghui Li; Julia H Aronson; Cole M Howie; Sanjay Maraboyina; Arpan V Prabhu; Thomas Kim Journal: Breast Date: 2020-03-06 Impact factor: 4.380